Table 6.

Comparison of outcomes in patients who developed dnDSA by induction group

VariableAlemtuzumab (N=12)Basiliximab (N=27)ATG (N=14)P Value
Development of dnDSA at 1 yr, % (n)14 (12)5 (27)8 (14)0.0009
Sum MFI of dnDSA at first test, median (interquartile range)1179 (640.3–2335)2264 (1231–8252)2138 (752.3–5642)0.27
Number of DSA contributing to sum MFI, mean±SD1.6±0.92.1±1.92.0±1.60.70
Days to development of dnDSA, mean±SD172.1±112198.6±95.3163.2±104.90.53
Steroid status, % (n)<0.001
 Early steroid withdrawal83 (10)0 (0)14 (2)
 Maintenance steroids17 (2)100 (27)86 (12)
Graft survival at 1 yr, % (n)100 (12)96 (26)100 (14)0.61
Graft survival overall, % (n)75 (9)93 (25)93 (13)0.24
Rejection at 1 yr, % (n)
 AMR17 (2)15 (4)14 (2)0.98
 ACR42 (5)30 (8)21 (3)0.53
Rejection overall, % (n)
 AMR17 (2)19 (5)14 (2)0.94
 ACR42 (5)33 (9)21 (3)0.53
  • dnDSA, de novo donor-specific antibody; ATG, anti-thymocyte globulin; MFI, mean fluorescence intensity; AMR, antibody-mediated rejection; ACR, acute cellular rejection.